2,4-Dichloropyrimidine → 2-Chloro-4-[6-methyl-4-(4-trifluoromethylphenyl)-pyridin-2-yl]-pyrimidine
반응식
I[C:2]1[CH:7]=[C:6]([C:8]2[CH:13]=[CH:12][C:11]([C:14]([F:17])([F:16])[F:15])=[CH:10][CH:9]=2)[CH:5]=[C:4]([CH3:18])[N:3]=1.[Cl:19][C:20]1[N:25]=[C:24](Cl)[CH:23]=[CH:22][N:21]=1>>[Cl:19][C:20]1[N:25]=[C:24]([C:2]2[CH:7]=[C:6]([C:8]3[CH:13]=[CH:12][C:11]([C:14]([F:17])([F:16])[F:15])=[CH:10][CH:9]=3)[CH:5]=[C:4]([CH3:18])[N:3]=2)[CH:23]=[CH:22][N:21]=1참가 물질
3
실험 절차
The title compound was prepared from 2-iodo-6-methyl-4-(4-trifluoromethyl-phenyl)-pyridine (example A.31) (10.89 g, 30 mmol) and commercially available 2,4-dichlorpyrimidine (4.47 g, 30 mmol) according to the general procedure IVc protocol b. Obtained as an off-white solid (7.2 g, 68%). MS (ISP) 350.2 [(M+H)+] and 352 [(M+2+H)+].
출처 및 근거
- ORD 기록
- ord-f155a24b82114b8aac39b9421219b6b6
- 출처 데이터셋
- uspto-grants-2012_05